Who makes Rosuvamibe® Tab?

Rosuvamibe® Tab is developed by Yuhan Corporation.

What development phase is Rosuvamibe® Tab in?

Rosuvamibe® Tab is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Rosuvamibe® Tab

Yuhan Corporation · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Rosuvamibe® Tab
Sponsor	Yuhan Corporation
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes (PHASE4)
A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia (PHASE4)
Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rosuvamibe® Tab CI brief — competitive landscape report
Rosuvamibe® Tab updates RSS · CI watch RSS
Yuhan Corporation portfolio CI